NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
13 hedge funds and large institutions have $632K invested in NRX Pharmaceuticals Warrant in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 13 → 13 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
30% less capital invested
Capital invested by funds: $904K → $632K (-$272K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$923 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$84K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$27 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $365K | -$27 | -100 | -0.3% |
|
|
PAMP
2
Polar Asset Management Partners
Toronto,
Ontario, Canada
| $95K | – | – | – |
|
|
VAS
3
VR Advisory Services
Camana Bay, Grand Cayman,
Cayman Islands
| $42K | – | – | – |
|
|
RCM
4
Rivernorth Capital Management
West Palm Beach,
Florida
| $31K | – | – | – |
|
|
AA
5
AQR Arbitrage
Greenwich,
Connecticut
| $26K | – | – | – |
|
|
6CM
6
683 Capital Management
New York
| $21K | – | – | – |
|
|
YCM
7
Yakira Capital Management
Westport,
Connecticut
| $21K | – | – | – |
|
|
GCL
8
Glazer Capital LLC
New York
| $17K | – | – | – |
|
9
Walleye Trading
New York
| $5K | – | – | – |
|
|
HF
10
HRT Financial
New York
| $3K | – | – | – |
|
|
LIM
11
Longfellow Investment Management
Boston,
Massachusetts
| $3K | – | – | – |
|
|
HIM
12
HGC Investment Management
Toronto,
Ontario, Canada
| $2K | – | – | – |
|
|
13
UBS Group
Zurich,
Switzerland
| $1K | +$923 | +3,475 | New |
|
|
14
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$84K | -187,500 | Closed |
|
NRXPW Hedge Fund Activity: Q3 2020 in Review
13 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q3 2020, worth a combined $632K — down 30% from $904K a quarter earlier.
Fund positioning in NRXPW was balanced in Q3 2020: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $923. The largest seller was Hudson Bay Capital Management, exiting entirely with an estimated $84K sold.
- 13 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $632K of NRX Pharmaceuticals Warrant stock for Q3 2020, down 30% quarter-over-quarter.
- 1 fund opened new NRX Pharmaceuticals Warrant positions in Q3 2020 and 1 closed out, a net change of 0 holders.
- The largest NRX Pharmaceuticals Warrant buyer in Q3 2020 was UBS Group, an estimated $923 added.
- The largest NRX Pharmaceuticals Warrant seller in Q3 2020 was Hudson Bay Capital Management, an estimated $84K sold.
Based on aggregated 13F filings for Q3 2020.